fasudil has been researched along with Arterial Occlusive Diseases in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hitomi, A | 1 |
| Satoh, S | 1 |
| Ikegaki, I | 1 |
| Suzuki, Y | 1 |
| Shibuya, M | 1 |
| Asano, T | 1 |
1 other study available for fasudil and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterial Occlusive Diseases; Blood Viscosity | 2000 |